Both ABP-671 and ABP-745 have the potential to give gout patients more effective and safer alternatives to existing gout therapies.

Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...

Despite the mechanisms that made it a “biologically plausible” candidate, the study found that participants who took the drug ...

Maybe your doctor just told you that you have gout and prescribed a high dose of ibuprofen and colchicine. When you get home, you might realize you can’t remember the side effects they listed while ...

A scientific statement has been published by the American College of Cardiology regarding inflammation and cardiovascular disease.

The drug colchicine may reduce cardiovascular outcomes among patients with gout, based on a range of retrospective data that ...

In patients with gout, a novel prediction tool that relies on weight and creatinine clearance successfully identified the ...

EPFL researchers have uncovered how transcription factor dosage reshapes cell identity, showing that even small differences ...

What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to get a fifth dose out of Mounjaro.

Yorvipath (palopegteriparatide) comes as a liquid solution that’s given as an injection under your skin. You’ll usually give yourself one injection of Yorvipath each day. The typical starting dose is ...

This is read by an automated voice. Please report any issues or inconsistencies here. If you’ve injected your weight-loss medication in an airport bathroom, you’re not alone. Or maybe you decided to ...

The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, ...